Introduction
Covid-19 broke out in 2019 and spread rapidly. Confirmed cases could be
found in countries around the world. The novel coronavirus has a raised
spike glycoprotein on its surface. The S glycopretein of the virus binds
to angiotensin converting enzyme 2 of the recipient cell, which causes
the virus to enter the cell. Viruses can also enter cells through
membrane fusion and release nucleic acids to synthesize new viruses,
causing cytopathic disease and death, thus leading to tissue and organ
lesions. Novel Coronavirus is mainly related to pulmonary infection,
which can involve multiple organs such as liver, spleen, cardiovascular
and cerebrovascular systems, stomach and esophagus, etc. In serious
cases, it can develop into acute respiratory distress syndrome,
metabolic acidosis and multi-organ dysfunction syndrome, or even death.
The initial clinical symptoms are mostly fever, dry cough and fatigue. A
few patients are accompanied by nasal congestion, runny nose, pharyngeal
pain, myalgia and diarrhea, some patients may have no obvious symptoms.
Previous studies[1] suggest that the
most prevalent comorbidities were hypertension(17%),DM (8%) and CVD
(5%) in COVID-19. It is important to evaluate patients’ clinical
symptoms based on current influencing factors and comorbidities.
Therefore, it is necessary to evaluate possible factors that may result
the progression or improvement of COVID-19 patients. Therefore,
the influencing factors of status for COVID-19 patients and the result
was investigated and analyzed in order to provide guidance about the
treatment of this disease.